Furosemide Injection Preceded a Fatal Case of Toxic Epidermal Necrolysis in a Toddler
Toxic epidermal necrolysis is among the most severe drug-related skin emergencies seen in clinical practice. The syndrome is defined by widespread epidermal detachment and mucosal injury, and when the process advances beyond 30% of total body surface area, the physiologic consequences can become rapidly catastrophic. Fluid loss, impaired temperature control, electrolyte instability, and infection risk can all follow within hours to days. In this case, a one-year-old girl developed a severe generalized eruption shortly after receiving a furosemide injection, adding a rare pediatric example to a reaction that is already feared for its speed and lethality.
The timeline matters. Her skin eruption began two days after the injection, which places the drug exposure close enough to fit a causal drug reaction pattern in a child with no alternative trigger described in the clinical summary. On admission, the eruption had already progressed to extensive sloughing over the face, trunk, and limbs, with 60% total body surface area involvement. In practical terms, this was not a limited rash or a benign exanthem; it was a full-thickness cutaneous emergency with the potential to compromise the skin barrier on nearly two-thirds of the body.
Extensive Skin Sloughing and Mucocutaneous Injury Defined the Presentation
The clinical picture was consistent with toxic epidermal necrolysis rather than a routine hypersensitivity reaction. The disorder is marked by keratinocyte death and separation of the epidermis from the dermis, a process that explains the sheet-like detachment seen in severe cases. Mucous membranes are frequently affected as well, and although the case summary emphasizes skin involvement, the diagnosis itself signals a broader mucocutaneous insult. Once the skin barrier fails at this scale, bedside care becomes as much about organ support as about dermatology.
The setting also deserves attention. The child came from Eastern Uganda and was referred after the eruption had already advanced. Referral delays are common in low-resource settings, where early recognition of severe cutaneous adverse drug reactions may be challenging and access to specialized supportive care can be limited. A one-year-old cannot describe pain, burning, or eye or mouth symptoms in the way an older child or adult might, so the burden of recognition falls entirely on caregivers and clinicians.
One injection preceded a life-threatening skin failure syndrome.
Supportive Care Remained the Core Treatment
After admission, the child was started on supportive care. No disease-specific rescue therapy was described in the case summary, which is consistent with real-world management of toxic epidermal necrolysis in many settings, where meticulous supportive treatment remains the foundation of care. The priorities are straightforward even when the disease itself is not: stabilize fluids, protect the denuded skin, prevent secondary infection, monitor pain, and preserve nutrition and organ function.
The report states that she initially improved. In toxic epidermal necrolysis, early improvement can create a fragile sense of momentum, because the inflammatory phase may begin to settle even while the patient remains physiologically vulnerable. Large denuded surfaces can continue to pose infection and dehydration risks long after the first signs of cutaneous recovery appear. For a toddler, the margin for error is especially small.
Her course ended after the parents left the hospital against medical advice, and she later died at home. That outcome is a stark reminder that severe cutaneous drug reactions do not end when the visible eruption begins to improve. They require sustained inpatient care, continuous observation, and family engagement until the risk of systemic deterioration has passed. When care is interrupted, the skin may be only the most visible sign of a still-active multisystem threat.
Why Furosemide Remains a Plausible Trigger
The case report links furosemide to toxic epidermal necrolysis and notes its structural similarity to sulphonamide antibiotics. That pharmacologic relationship is clinically relevant because severe cutaneous adverse reactions are often discussed in the context of drug hypersensitivity pathways rather than simple dose-related toxicity. The immune system appears to recognize a drug or drug-related metabolite as a danger signal, leading to widespread keratinocyte injury in susceptible individuals. Even though furosemide is widely used, rare idiosyncratic reactions can still occur, and pediatric cases are particularly important because they may be missed or misattributed.
Structural similarity does not prove causation in a single patient, but it strengthens biologic plausibility when the chronology is tight and the phenotype is classic. Here, the eruption began two days after exposure, then progressed to extensive sloughing with a distribution involving the face, trunk, and limbs. The pattern is difficult to dismiss as coincidental when measured against the severity of the reaction and the temporal relationship to the injection.
A Rare Pediatric Signal With Direct Bedside Consequences
The value of this case is not in frequency; it is in recognition. Severe drug eruptions in children are often initially approached as infectious exanthems, viral syndromes, or nonspecific allergic rashes, especially early in the course. Once epidermal detachment appears, however, the differential narrows quickly and the need for urgent withdrawal of the suspected agent and intensive supportive care becomes immediate. The earlier the condition is recognized, the greater the chance of reducing complications from fluid loss, sepsis, and metabolic instability.
This report also widens clinical awareness around medications not always at the top of the differential for toxic epidermal necrolysis. Furosemide is common in practice, which makes rare adverse events easy to overlook. When a child develops a rapidly progressive blistering eruption after drug exposure, especially with mucocutaneous involvement or sheet-like sloughing, the possibility of a severe cutaneous adverse reaction has to remain front and center.
The case closes with a fatal outcome after discharge, not with resolution in a controlled setting. That ending is the hardest part of the story: a potentially survivable drug reaction became fatal once close monitoring stopped. It is a reminder that the diagnosis is only the beginning, and that for pediatric toxic epidermal necrolysis, uninterrupted supportive care can be the difference between recovery and death.